Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 vs Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous NSCLC With Genomic Alterations
NCT06074588Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 25
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Nov 2023; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06074588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06074588.